Sanofi shows off positive PhIII trial results for Toujeo, opening the door to a new group of diabetes patients

A little under two months since their latest setback in diabetes R&D as their dominant perch in the market is shaken by severe headwinds, Sanofi had some positive results to report Monday from a Phase III trial applying its Lantus insulin followup in childhood and adolescent type 1 diabetes.